Drug Uses

Microzide is used for the treatment of edema, and for high blood pressure.

How Taken

It it recommended that you take Microzide early in the day. Take this medicine with milk or food to reduce the risk stomach pain.

Warnings/Precautions

Tell your doctor your medical history, especially about: gout, diabetes, liver problems, urinary problems, any allergies.

Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time for the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Possible Side Effects

Some of the side effects that may occur while taking Microzide include: black, tarry stools; blood in urine or stools; cough or hoarseness; fever or chills; joint pain; lower back or side pain; painful or difficult urination; pinpoint red spots on skin; skin rash or hives; stomach pain with nausea and vomiting; unusual bleeding or bruising; yellow eyes or skin. If you experience bothersome side effects, stop taking Microzide and contact your doctor or local pharmacist.

Storage

Store this medicine at room temperature below 86 degrees F (30 degrees C) in a tightly-closed container, away from heat, moisture, and light. Keep out of the reach of children.

Overdose

If overdose is suspected, seek immediate medical attention. Symptoms of overdose may include unconsciousness, nausea/vomiting, weakness, slow or shallow breathing, dizziness, confusion, unusually slow heartbeat, seizures, drowsiness, or fainting.

More Information

Use caution when driving, operating machinery, or performing other hazardous activities. Detrol may cause dizziness, drowsiness, or blurred vision. If you experience dizziness, drowsiness, or blurred vision, avoid these activities.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

---

Microzide has been a resource for health information for several years. Our staff has over a century of collective experience working with medicines.
We work through Microzide to offer you a variety of health products at reasonable prices.
Our mission is to promote health.
We work to make our Microzide accessible in the context of a multi-cultural, physically and economically diverse community.
It is our goal to provide a wide range of information and products for health, including the full continuum of health care options and philosophies.

Q: Do you deliver Microzide to my state?
A: Due to regulations we cannot ship medicines to all states, please check the order form for the current list of states that we can ship to.


Even as Evista (raloxifene) reduced the risk of invasive breast cancer by 44%, compared with placebo, it had a significantly increased relative risk of thromboembolic events -- including fatal strokes -- according to a study of more than 10,000 postmenopausal women.
Evista was associated with a 49% increase in the relative risk of fatal stroke (P=0.05), Elizabeth Barrett-Connor, M.D., of the University of California San Diego and colleagues for the RUTH (Raloxifene Use for The Heart) trial reported in the July 13 issue of the New England Journal of Medicine.
Evista was also associated with a significant increase in risks of venous thromoboembolic events (P=0.02), but as expected Evista was associated with a significant decrease in risk of clinical vertebral fractures (P=0.007).
The 44% decrease in invasive breast cancer risk (P=0.003) among women taking Evista was driven by a highly significant reduction in estrogen-positive breast cancer (P<0.001). Evista did not reduce the risk of estrogen-negative breast cancers (P=0.40).
Women taking Evista also had significantly more hot flushes, leg cramps, and peripheral edema (P<0.001 for all compared with placebo), they wrote.
The RUTH investigators randomly assigned 10,101 postmenopausal women (mean age 67.5) with established coronary heart disease or multiple risk factors for heart disease to either 60 mg of Evista daily or placebo. The women were followed for a median of 5.6 years. The primary endpoints were coronary events and invasive breast cancer.
In this group of women at high risk for coronary events, "the difference in absolute rates of events that were decreased (i.e., breast cancer and clinical vertebral fractures) was similar to the difference in the absolute rates of events that were increased (i.e., venous thromboembolic events and fatal strokes)," the authors wrote.
And that may be the sticking point for many clinicians counseling women, said Steven Nissen, M.D., acting director of cardiology at the Cleveland Clinic.
"When a drug increases cardiovascular risk, we have to take that seriously," he said adding that Dr. Barrett-Connor and colleagues did an excellent job of "laying out the risks and benefits very clearly, with no spin."
Dr. Nissen, who was an early critic of Vioxx (rofecoxib) because of its increased risk of thromboembolic events, said that results of the RUTH trial are likely to spur debate if Lilly, the maker of Evista, seeks FDA approval for Evista for breast cancer prevention.
Currently the drug is approved for treatment and prevention of osteoporosis in postmenopausal women.
Earlier this year, results of the STAR (Study of Tamoxifen and Raloxifene) trial indicated that Evista is as effective as tamoxifen for preventing breast cancer in postmenopausal women. Tamoxifen is the only FDA approved drug for prevention of breast cancer.
Lilly said in June that it plans to ask the FDA to approve Evista for cancer prevention.
Evista and tamoxifen are both selective estrogen receptor modulators, or SERMs. SERMs were originally developed as alternatives to estrogen to treat symptoms of menopause as well as osteoporosis. But unlike estrogen, SERMs do not reduce vasomotor symptoms, although they have demonstrated efficacy in osteoporosis.
When the RUTH trial began recruiting women in 1998 it was widely believed that estrogen reduced the risk of coronary events, which led Dr. Barrett-Connor and colleagues to hypothesize that Evista would also be cardio-protective. But in 2002, investigators for the Women's Health Initiative reported that estrogen increased the risk of stroke and thromboembolic events, as well as increasing the risk of breast cancer.
The RUTH results "now allow us to say that all modulators of the estrogen receptors potentially increase the risk of cardiovascular events," said Dr. Nissen.
John T. Cole, M.D., medical director of hematology and oncology services at the Ochsner Health System in New Orleans, said that the RUTH findings coming on the heels of the STAR trial confirm that Evista has a role in chemoprevention in a select population -- but defining that population may be difficult.
Even so-called high risk women only have very small absolute risk for developing breast cancer, he said. "If you look at in terms of telling a woman that she has about a 98.4% chance of [not developing breast cancer], it is difficult to imagine her wanting chemoprevention," he said.
Nonetheless, Dr. Cole said that in both the RUTH trial and the STAR trial "as risk increased, so did the potential benefit of chemoprevention."
In an NEJM editorial, Marcia L. Stefanick, Ph.D., of the Stanford Prevention Research Center in Stanford, Calif., said the RUTH study "highlights the need to consider the risk of breast cancer as well as other risks and coexisting conditions in determining whether and when [Evista] or another SERM is warranted for an individual woman."
"For women represented by the RUTH cohort of women with or at increased risk for CHD, the moderate benefits of raloxifene for breast cancer prophylaxis do not seem to justify the risks" she wrote.
"For now," Dr. Stefanick continued, "there is no magic bullet that can reduce the risks of major health problems related to estrogens and aging without introducing other potentially serious health concerns."

Frequent Microzide misspellings: nicrozide, kicrozide, jicrozide, mucrozide, mjcrozide, mkcrozide, mocrozide, m9crozide, m8crozide, mixrozide, mivrozide, mifrozide, midrozide, miceozide, micdozide, micfozide, mictozide, mic5ozide, mic4ozide, micrizide, micrkzide, micrlzide, micrpzide, micr0zide, micr9zide, microxide, microside, microaide, microzude, microzjde, microzkde, microzode, microz9de, microz8de, microzise, microzixe, microzice, microzife, microzire, microziee, microzidw, microzids, microzidd, microzidr, microzid4, microzid3, icrozide, mcrozide, mirozide, micozide, micrzide, microide, microzde, microzie, microzid, imcrozide, mcirozide, mircozide, micorzide, micrzoide, microizde, microzdie, microzied, mmicrozide, miicrozide, miccrozide, micrrozide, microozide, microzzide, microziide, microzidde, microzidee

Microzide search phrases: Microzide medicine, Microzide prescription, Microzide uses, Microzide without rx, Microzide pill, Microzide purchase, Microzide no prescription, Microzide mail order, Microzide brand name, Microzide fedex delivery, Microzide without prescription, Microzide for sale, Microzide order